Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis

Summary

The goal of this clinical trial is to analyse efficacy and safety of ixekizumab in participants with refractory guttate psoriasis. The main question it aims to answer is: What percentage of participants achieved more than 90% reduction from baseline in Psoriasis Area Index （PASI 90） after 12 weeks of ixekizumab treatment? Participants will receive a 12-week treatment of ixekizumab, with follow-up visits every 2 weeks during the treatment period. Keep a diary of their symptoms and Psoriasis Area Index.

Timeline

Start

2025-05

Primary completion

2025-06

Completion

2026-06

Drugs

Indications